# Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

> **NCT01303549** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 61 (actual)

## Conditions studied

- Liver Disease
- Fungal Infection

## Interventions

- **DRUG:** Anidulafungin
- **DRUG:** Liposomal amphotericin B

## Key facts

- **NCT ID:** NCT01303549
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303549, "Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01303549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*